Zika and dengue viruses remain significant public health threats. These viruses share the same Aedes (Stegomyia) mosquito vectors and geographic distributions but infections cannot be readily distinguished clinically and need to be differentiated from each other, and from other circulating arboviral... and non-arboviral pathogens, using laboratory tests. This document provides guidance on current testing strategies for Zika and dengue virus infections with updates to the previous interim guidance for laboratory testing for ZIKV, addressing pregnant and non-pregnant patients respectively, and incorporates current guidance for dengue virus diagnostic testing. The choice of laboratory assays and interpretation of test results require careful consideration of epidemiology, patient history, and limitations of existing diagnostic tests.
This interim guidance is for use by staff of laboratories testing for Zika and dengue virus infections and for clinical practitioners and public health professionals providing clinical management or surveillance.
more
GPHF Minilab manuals on basic dye and thin layer chromatographic testing. The newest version of the manual (Volume I + II) from 2008 is available in three languages: English, French, Spanish. Combining the main manual with the supplements issued each year between 2010 and 2015, label claims on drug... identity and content can now be verified for 75 active ingredients and their fixed-dose combination products using simple, rapid and affordable thin layer chromatographic tests. Please note: Only the demo versions are online available!! The complete manuals are only available after purchasing the Minilab!
more
Volume 3, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The DCP3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alternative cancer care packa...ges that are cost-effective and suited to low-resource settings. Main messages from the volume include:
-Quality matters in all aspects of cancer treatment and palliation.
-Cancer registries that track incidence, mortality, and survival paired with systems to capture causes of death are important to understanding the national cancer burden and the effect of interventions over time.
-Effective interventions exist at a range of prices. Adopting ‘resource appropriate’ measures which allow the most effective treatment for the greatest number of people will be advantageous to countries.
-Prioritizing resources toward early stage and curable cancers is likely to have the greatest health impact in low income settings.
-Research prioritization is no longer just a global responsibility.
more
La publicación consiste en un instrumento de gestión, que permite unificar los criterios de manejo clínico operacional en la lucha contra la tuberculosis y contribuye a que esta enfermedad deja de ser un problema de salud pública en nuestro país.
Technical specifications series for submission to WHO prequalification: diagnostic assessment;TSS-3
Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries.
In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response.
As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa.
more
This manual is to assist health care providers and laboratory scientists to diagnose mycobacterium ulcerans disease (Buruli ulcer). The manual aims to achieve a better understanding of the clinical presentation and its diagnosis. The methods described are tailored to various levels of care and avail...able resources to improve the diagnosis and surveillance of the disease.
more
Manuel destiné au personnel soignant.
Ce manuel s'adresse aux professionnels de la santé confrontés à la maladie à Mycobacterium ulcerans (ulcère de Buruli). Il vise à mieux faire comprendre la maladie, sa présentation clinique et sa prise en charge chirurgicale. Il s'adresse en particuli...er aux prestataires de soins de santé des districts. Il présente un protocole complet, adapté à chaque forme et à chaque stade de la maladie, ainsi que des commentaires sur les niveaux de ressources et de capacités nécessaires pour raccourcir la durée du traitement.
more
Le suivi évaluation des interventions en santé passe par une meilleure lisibilité de l’analyse situationnelle. Une capitalisation du niveau d’atteintes des indicateurs est nécessaire pour traduire la situation sanitaire. Le présent tableau de bord de santé décrit cette situation à traver...s une appréciation objective des performances du système de santé en rapport avec la mise en œuvre des différentes stratégies et politiques telles le Plan national de développement sanitaire (PNDS), la Stratégie de croissance accéléré de développement durable (SCADD), les Objectifs du millénaire pour le développement (OMD) etc.
Son élaboration a requis un processus participatif avec la participation des acteurs du
système de santé notamment les structures centrales, les projets et programmes, les
acteurs du niveau intermédiaire, périphérique avec l’appui technique des partenaires. Audelà du caractère descriptif de la situation sanitaire, il apparait comme un outil de plaidoyer et interpelle sur les efforts à consentir pour une amélioration de l’état de santé des populations. Il comporte six sections que sont (i) les données générales, (ii) les ressources en santé, (iii) la santé de la mère et de l’enfant, (iv) les maladies à potentiel épidémique, (v) les maladies d’intérêt spécial, (vi) l’utilisation des services de santé.
more
Politique Nationale de Promotion de la Santé, Version Finale